Will an oral GLP-1 weight-loss drug receive FDA approval by end of 2026?

Oral semaglutide and rival compounds are in late-stage trials. An OTC pathway would massively expand the addressable market.

Yes58%42%No

Volume

$3.18M

Traders

20.4K

Liquidity

$680K

Yes Price

$0.58

Probability History

Select Outcome

Prices include spread.

Select an outcome to start trading

Amount (USD)

You Pay—

Fee (1%, incl.)—

Trade Amount—

Shares—

Current Price—

Max Payout—

Max profit if correct—

Mock mode — no real funds used

Oral semaglutide and rival compounds are in late-stage trials. An OTC pathway would massively expand the addressable market.

You can read comments as a guest, but posting requires an account

Loading comments…